Abstract: The invention relates to the use of ligands to GABAB receptors for increasing neurotrophin levels in the central nervous system.

Abstract: The invention relates to the use of ligands to GABAB receptors for increasing neurotrophin levels in the central nervous system.

Abstract: Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.3 are hydrogen.

Abstract: Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.

Abstract: Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.

Abstract: Compounds of the class of (2-benzofuranyl)-1,2,3,6-tetrahydropyridines and (2-benzofuranyl)-piperidines which at the ring nitrogen atom are unsubstituted or substituted by a substituent of the class of certain aliphatic, cycloaliphatic and araliphatic radicals, and their pharmaceutically acceptable acid addition salts have valuable pharmacological properties. In particular, they inhibit monoamine oxidase and antagonise the action of tetrabenazine. They are useful as active ingredients for therapeutic compositions for the treatment of mental depression. Specific embodiments are 4-(2-benzofuranyl)-piperidine, 2-(5,6-dimethyl-2-benzofuranyl)-piperidine and their hydrochlorides.

Abstract: Oxothia compounds, especially 2-oxo-2,3-dihydro-benzo[b]-thiophene compounds of the formula ##STR1## in which Ph represents an optionally substituted 1,2-phenylene radical, X represents oxygen or sulphur, R.sub.1 represents an organic radical bonded via a carbon atom and R.sub.2 denotes hydrogen or an optionally substituted hydrocarbon radical of aliphatic character, and their salts are useful as peripheral analgetics and/or as antiphlogistic uricosuric and/or thrombolytic agents.

Abstract: Oxothia compounds, especially 2-oxo-2,3-dihydro-benzo[b]-thiophene compounds of the formula ##STR1## in which Ph represents an optionally substituted 1,2-phenylene radical, X represents oxygen or sulphur, R.sub.1 represents an organic radical bonded via a carbon atom and R.sub.2 denotes hydrogen or an optionally substituted hydrocarbon radical of aliphatic character, and their salts are useful as peripheral analgetics and/or as antiphlogistic uricosuric and/or thrombolytic agents.

Abstract: Oxothia compounds, especially 2-oxo-2,3-dihydro-benzo[b]thiophene compounds of the formula ##STR1## in which Ph represents an optionally substituted 1,2-phenylene radical, X represents oxygen or sulphur, R.sub.1 represents an organic radical bonded via a carbon atom and R.sub.2 denotes hydrogen or an optionally substituted hydrocarbon radical of aliphatic character, and their salts are useful as peripheral analgetics and/or as antiphlogistic uricosuric and/or thrombolytic agents.

Abstract: The present invention provides new benzofuranyl-tetrahydropyridines and -piperidines of the general formula I ##STR1## in which R.sub.1 and R.sub.2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R.sub.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y.sub.1 and Y.sub.2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number not more than 35, cyano or hydroxyl and the pharmaceutically acceptable acid addition salts thereof, and antidepressant preparations containing these compounds. The compounds according to the invention have valuable pharmacological properties.

Abstract: Compounds of the class of (2-benzofuranyl)-1,2,3,6-tetrahydropyridines and (2-benzofuranyl)-piperidines which at the ring nitrogen atom are unsubstituted or substituted by a substituent of the class of certain aliphatic, cycloaliphatic and araliphatic radicals, and their pharmaceutically acceptable acid addition salts have valuable pharmacological properties. In particular, they inhibit monoamine oxidase and antagonize the action of tetrabenazine. They are useful as active ingredients for therapeutic compositions for the treatment of mental depression. Specific embodiments are 4-(2-benzofuranyl)-piperidine, 2-(5,6-dimethyl-2-benzofuranyl)-piperidine and their hydrochlorides.

Abstract: Compounds of the formula ##STR1## in which Ar represents optionally substituted 1,2-phenylene, X.sub.1 represents oxygen or sulphur, R.sub.1 represents the radical of the formula ##STR2## in which Ph represents optionally substituted phenylene, X.sub.2 represents oxygen or sulphur, R.sub.3 and R.sub.4 independently of one another denote hydrogen or alkyl and R.sub.5 represents optionally etherified hydroxyl or optionally substituted amino and in which R.sub.2 denotes hydrogen, lower alkyl or the radical of the formula Ia and one of the groups R.sub.1 and R.sub.2 takes up the 2-position and the other takes up the 3-position, and salts of such compounds having salt-forming groups, e.g. ethyl 2-[4-(2-benzofuranyl)-phenoxy]-heptanoate. These compounds may be used as fibrinolytic and thrombolytic agents.

Abstract: 9-(2-A-3-R-propyl)-9,10-dihydro-9,10-ethano-anthracenes containing the nucleus of the formula ##STR1## wherein R denotes a secondary or tertiary amino group and A denotes a free, etherified or acylated hydroxyl group, their pharmaceutically acceptable salts are useful as psychotropics, especially as anti-depressants.

Abstract: 9-(2-A-3-R-propyl)-9,10-dihydro-9,10-ethanoanthracenes containing the nucleus of the formula ##STR1## wherein R denotes a secondary or tertiary amino group and A denotes a free, etherified or acylated hydroxyl group, their pharmaceutically acceptable salts are useful as psychotropics, especially as anti-depressants.

Abstract: The invention relates to a process for the production of new benzo[b]thiophenes of formula I ##SPC1##whereinPH is optionally substituted o-phenylene, one of the radicals R.sub.1 and R.sub.2 is hydrogen or lower alkyl, and the other of the radicals R.sub.1 and R.sub.2 is optionally C-substituted piperidyl which optionally carries hydroxy on the ring-C-atom bound to the benzo[b]thienyl radical, or which optionally contains a C-C-double bond emanating from this C-atom, and which optionally carries on the N-atom a hydrocarbon radical of aliphatic character, which radical is optionally substituted in a position higher than the 1-position, and of their acid addition salts.These new compounds possess valuable pharmacological properties. In particular they inhibit mono-amine oxidase and further inhibit the absorption of noradrenaline and serotonine in the brain. They are useful as active substances for pharmaceutical preparations for the treatment of mental depressions and psychoses.